


Prost-P10x[®]

Description

Prost-P10x is a clinical grade natural supplement program for men who are looking to restore their prostate health as close as possible to youthful levels.

Therapeutic Benefits for Prostate Health

Prost-P10x is Doctor formulated and delivers therapeutic dosages (over 3320mg + 1000IU's) of the same combination (patented and trademarked) natural ingredients that formed the basis of the major prostate health research studies and successful clinical trials. The Prost-P10x ingredients are delivered in a single, convenient, daily dose packet containing six (6) capsules.



Doctor Formulated based on Science and Research

Prost-P10x was developed by Dr. Geo Espinosa, N.D., L.Ac, CNS, RH (AHG). Dr. Geo is the Director of the Integrative Urology Center at New York University Langone Medical Center and the Chief Science Officer at Prostate Research Labs.

Before founding NYU's Department of Integrative Urology, Dr. Geo was a clinician, researcher and the Director of Clinical Trials at the Center for Holistic Urology at Columbia University Medical Center.

Dr. Geo is one of only 3 Naturopathic Doctors in the USA who focus exclusively on men's urological health. He is a frequent speaker at universities, medical schools and conferences on Integrative Health, nutrition and natural treatments for prostate health.

Prost-P10x is the culmination of Dr. Geo's research into over 500 studies and his personal experience in his Naturopathic Urology Practice as to what works and what doesn't in restoring prostate health.

Ingredients

The active, 100% natural ingredients in Prost-P10x have been shown in research studies and clinical trials to:

- Promote proper prostate size*
- Support normal urinary flow and volume*
- Encourage healthy libido and sexual response*
- Support the natural response to DHT (dihydrotestosterone) reduction*
- Assist the natural regulation of 5-alpha-reductase which affects normal prostate size and volume*
- Support overall prostate and urinary health*
- Restore prostate health as close as possible to youthful levels *
- Help promote cellular and immune system health*

Supplement Facts		
Serving Size 1 Pack (6 capsules)		
Servings Per Container 30		
Amount Per Serving		%DV
Vitamin D-3	1,000 IU	250%
Zinc (as Zinc Citrate).....	15 mg	100%
Graminex G63™ Flower Pollen Extract	500 mg	*
(Secale cereal L., containing fat and water soluble fractions in a 20:1 ratio)		
Quercetin dihydrate	500 mg	*
Saw Palmetto Extract.....	640 mg	*
(Serenoa repens, (fruit) 45% fatty acids)		
Meriva® Curcumin Phytosome	160 mg	*
(Curcuma longa extract, rhizome)/ Phosphatidylcholine (soy) complex)		
Green Tea Leaf Extract	500 mg	*
(Camellia sinensis standardized to 45% EGCG)		
Cranberry (Vaccinium macrocarpon, fruit)	500 mg	*
Stinging Nettle (Urtica dioica, root).....	240 mg	*
Plant Sterols (as beta sitosterol).....	65 mg	*
Pygeum africanum (bark).....	100 mg	*
3,3-Diindolylmethane (DIM)	100 mg	*

*Daily Value not established

Graminex (G63™) Pollen Extract (500mg) (Secale cereal L., containing fat and water soluble fractions in a 20:1 ratio): The G63™ Graminex rye pollen (cernilton) in Prost-P10x has been used for 35 years in Europe for prostatitis, BPH and to support healthy prostate volume and normal nighttime urination.

Organic Saw Palmetto Extract (640mg): The combined 640mg of saw palmetto (45% Fatty Acids) in Prost-P10x has been shown to be the most effective in studies in boosting prostate health and promoting a healthy libido.

Quercetin Dihydrate (500mg): (flavonoid complex) For more than a decade, quercetin has been recognized as a potent antioxidant as well as being beneficial in supporting overall prostate health, usually at a dose of 500 mg daily.

Beta-sitosterol (Plant Sterols) (65mg): Beta-sitosterol has been shown to affect the activity of the enzyme 5-alpha-reductase, which in turn may inhibit the production of dihydrotestosterone (DHT), which in turn helps promote proper prostate size and urinary tract health.

Green Tea Extract (leaf, 45% EGCG) (500mg): Green tea provides support for prostate health and normal prostate size. Green tea has also been shown in studies to regulate DHT production and hormones that influence prostate volume and PSA levels. The beneficial effects of taking green tea have been shown to increase with higher levels of green tea/EGCG dosage.

Vitamin D-3 (1000IU): Increasing supplemental D-3 intake is associated with a trend of promoting greater prostate health.

3,3-Diindolylmethane (DIM) (100mg): As men age, they experience a decline in testosterone and, in many cases, increases in estrogen levels. The result is a testosterone/ estrogen imbalance that emerging research suggests may impact overall prostate health. DIM naturally supports the testosterone/estrogen balance as well as promoting sexual energy and normal prostate size.

Cranberry (Vaccinium macrocarpon, fruit) (500mg): Cranberry provides natural support for urinary tract health as well as providing prostate health support. In 2004, France became the first country to approve a health claim for the American cranberry for urinary tract health.

Stinging Nettle (root) (240mg): Stinging Nettle Root supports urinary health and symptoms related to an aging prostate particularly when used with the saw palmetto and quercetin combination in Prost-P10x. The nettle root also naturally interacts with the binding of DHT providing a further mechanism of action for supporting prostate health.

Pygeum africanum (bark) (100mg): Pygeum is an herbal remedy derived from the bark of the Pygeum africanum tree that has been used since ancient times to promote bladder health. Pygeum also may reduce the number of receptor sites where DHT can attach to cells. Numerous studies have supported the use of Pygeum in the management of prostate health.

Meriva® Curcumin (160mg) Studies have shown that curcumin can help regulate the body's natural inflammation response and can provide support for prostate health. Meriva® has been shown to have up to a 20-fold improvement in bioavailability versus standard turmeric (95%) extracts.

Zinc (as Zinc Citrate) (15mg): Zinc is known to promote proper sexual function as well as support prostate health. The mineral is also a key player in the body's DNA-damage repair process.

Indications

Prost-P10x may be taken as a dietary supplement by men who wish to maximize prostate health and provide support for natural restoration of prostate size and urinary function. Prost-P10x also provides immunity and cellular health for men suffering from the affects of an aging or enlarged prostate.

Dosage Information

One packet a day (6 capsules) depending on individual level of prostate health. The full dosage may be taken all at once or throughout the day (preferably with meals). Men with more serious concerns about their prostate health may wish to double dose each day for the first week.

Side Effects

No adverse effects have been reported.

Storage

Keep in a cool, dry place, away from direct light. Keep out of reach of children

Other Information

- Packaged in a FDA audited Facility
- ISOP 9001 Certified Laboratory
- ISO 17025 Accredited Laboratory
- NSF GMP Facility Registration

- Manufactured by Douglas Laboratories
- CITES Certified Pygeum (proof of sustainable farming practices)
- Purchases support ZERO, The Project to End Prostate Cancer

References

Berges RR, Kassen A, Senge T. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up. *BJU Int* 2000 May; 85(7):842-6.

Berges RR, Windeler J, Trampisch HJ, et al. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. *Lancet* 1995; 345:1529-1532.

Jourdain C et al. In-vitro effects of polyphenols from cocoa and beta-sitosterol on the growth of human prostate cancer and normal cells. *Eur J Cancer Prev* 2006 Aug; 15(4): 353-61

Klippel KF, Hiltl DM, Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group. *Br J Urol* 1997; 80:427-432.

Wilt TJ et al. Beta-sitosterols for benign prostatic hyperplasia. *Cochrane Databases of Systematic Reviews* 2000; (2):CD001043

Howell AB et al. Dosage effect on uropathogenic *Escherichia coli* anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study. *BMC Infect Dis* 2010 Apr 14; 10(1): 94

Howell AB. Bioactive compounds in cranberries and their role in prevention of urinary tract infections. *Mol Nutr Food Res* 2007 Jun; 51(6): 732-37

Howell AB, Foxman B. Cranberry juice and adhesion of antibiotic-resistant uropathogens. *JAMA* 2002 Jun 19; 287(23): 3082-83

Kim SH et al. Do *Escherichia coli* extract and cranberry exert preventive effects on chronic bacterial prostatitis? *J Infect Chemother* 2010 Nov 2

Sengupta K et al. A randomized, double-blind, controlled, dose dependent clinical trial to evaluate the efficacy of a proanthocyanidin standardized whole cranberry (*Vaccinium*

macrocarpon) powder on infections of the urinary tract. *Current Bioactive Compounds* 2011 Mar; 7(1): 39-46

Vidlar A et al. The effectiveness of dried cranberries (*Vaccinium macrocarpon*) in men with lower urinary tract symptoms. *Br J Nutr* 2010 Oct; 104(8): 1181-89

Adhami VM et al. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. *Clinical Cancer Research* 2007; 13:1611-19.

Beliveau R, Gingras D. *Foods to Fight Cancer*. New York/London: DK Publishing, 2007.

Bettuzzi S et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. *Cancer Research* 2006; 66(2):1234-40.

Butt MS, Sultan MT. Green tea: nature's defense against malignancies. *Crit Rev Food Sci Nutr* 2009; 49(5):463-73.

Gupta S et al. Prostate cancer chemoprevention by green tea: in vitro and in vivo inhibition of testosterone-mediated induction of ornithine decarboxylase. *Cancer Research* 1999; 59(9):2115-20.

Gupta S et al. Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. *Toxicology & Applied Pharmacology* 2000; 164(1):82-90.

Heilbrun LK et al. Black tea consumption and cancer risk: a prospective study. *Br J Cancer* 1986; 54:677-83.

Hussain T et al. Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells. *Intl J Cancer* 2005; 113(4):660-69.

Jain MG et al. Alcohol and other beverage use and prostate cancer risk among Canadian Men. *Intl J Cancer* 1998; 78(6):707-11.

- Jian L et al. Protective effect of green tea against prostate cancer: a case-control study in southeast China. *Int J Cancer* 2004; 108(1):130-35.
- Kurahashi N et al for the JPHC Study Group. Green tea consumption and prostate cancer risk in Japanese men: a prospective study. *Am J Epidemiol* 2008; 167(1): 71-77.
- Lee YS et al. Synergistic effect between catechin and ciprofloxacin on chronic bacterial prostatitis rat model. *Int J Urol* 2005 Apr; 12(4): 383-89
- McLarty J et al. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. *Cancer Prev Res* 2009 Jun 19; online 10.1158/1940-6207.
- Yoon BI et al. Anti-inflammatory and antimicrobial effects of nanocatechin in a chronic bacterial prostatitis rat model. *J Infect Chemother* 2010 Aug 7
- Zhou JR et al. Soy phytochemicals and tea bioactive components synergistically inhibit androgen-sensitive human prostate tumors in mice. *J Nutr* 2003 Feb; 133(2): 516-21
- Ackerman GE, et al. Potentiation of epinephrine-induced lipolysis by catechol estrogens and their methoxy derivatives. *Endocrinology*. 1981; 109:2084-88.
- Dalessandri KM et al. Pilot study: effect of 3,3'-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. *Nutr Cancer*. 2004; 50(2):161-67.
- Hsu JC et al. Indole-3-carbinol mediated cell cycle arrest of LNCaP human prostate cancer cells requires the induced production of activated p53 tumor suppressor protein. *Biochem Pharmacol* 2006 Dec 15; 72(12): 1714-23
- Le HT et al. Plant-derived 3,3'-Diindolylmethane is a strong androgen antagonist in human prostate cancer cells. *J Biol Chem*. 2003 Jun 6; 278(23):21136-45.
- Li Y et al. Selective growth regulatory and pro-apoptotic effects of DIM is mediated by AKT and NF-kappaB pathways in prostate cancer cells. *Front Biosci*. 2005 Jan 1;10:236-43.
- Sarkar FH, Li Y. Indole-3-carbinol and prostate cancer. *J Nutr* 2004 Dec; 134(12 Supp): 3493S-98S
- Schneider J et al. Effects of obesity on estradiol metabolism: decreased formation of nonuterotropic metabolites. *J Clin Endocrinol Metab*. 1983 May; 56(5):973-78.
- Tofovic SP et al. 2-Hydroxyestradiol attenuates the development of obesity, the metabolic syndrome, and vascular and renal dysfunction in obese ZSF1 rats. *J Pharmacol Exp Ther*. 2001 Dec; 299(3):973-77.
- Wong GY et al. Dose-ranging study of indole-3-carbinol for breast cancer prevention. *J Cell Biochem Suppl* 1997; 28-29: 111-16
- Zeligs MA. The cruciferous choice: diindolylmethane or 13C?
- Zeligs MA. Phytochemicals for promoting weight loss. US Patent #6,534,085, 2003, March.
- Bercovich E, Saccomanni M. Analysis of the results obtained with a new phototherapeutic association for benign prostatic hyperplasia versus controls. *Urologia* 2010 Oct 2; 77(3): 180-86
- Cai T et al. *Serenoa repens* associated with *Urtica dioica* (ProstaMEV) and curcumin and quercetin (FlogMEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomized study. *Int J Antimicrob Agents* 2009 Jun; 33(6): 549-53
- Konrad L et al. Antiproliferative effect on human prostate cancer cells by a stinging nettle root (*Urtica dioica*) extract. *Planta Med* 2000; 66(1):44-47.
- Lopatkin N et al. Efficacy and safety of a combination of Sabal and *Urtica* extract in lower urinary tract symptoms—long-term follow-up of a placebo-controlled, double-blind, multicenter trial. *Int Urol Nephrol* 2007; 39(4): 1137-46.
- Safarinejad MR. *Urtica dioica* for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. *J Herb Pharmacother* 2005; 5(4):1-11.
- Schneider T, Rubben H. Stinging nettle root extract (Bazoton-uno) in long term treatment of benign prostatic syndrome (BPS). Results of a randomized, double-blind, placebo controlled multicenter study after 12 months. *Urologe A* 2004 Mar; 43(3): 302-6
- Sokeland J. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. *BJU Int* 2000;86:439-442.
- Buck AC et al. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, Cernilton. A double-blind, placebo-controlled study. *Br J Urol* 1990; 66(4):398-404.
- Chambliss WG. A critical review of Graminex flower pollen extract for symptomatic relief of lower urinary tract symptoms (LUTS) in men. National Center for Natural Products Research, 2003.
- Dutkiewicz S. Usefulness of cernilton in the treatment of benign prostatic hyperplasia. *Int Urol Nephrol* 1996; 28(1): 49-53
- Elist J. Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic

- nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double-blind, placebo-controlled study. *Urology* 2006 Jan; 67(1): 60-63
- Rugendorff EW et al. Results of treatment with pollen extract (Cernilton N) in chronic prostatitis and prostatodynia. *Br J Urol* 1993 Apr; 71(4): 433-38
- Talpur N et al. Comparison of saw palmetto (extract and whole berry) and cernitin on prostate growth in rats. *Mol Cell Biochem* 2003 Aug; 250(1-2): 21-26
- Wagenlehner FM et al. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomized, prospective, double-blind, placebo-controlled phase 3 study. *Eur Urol* 2009 Sep; 56(3): 544-51
- Wilt T et al. Cernilton for benign prostatic hyperplasia. *Cochrane Database Syst Rev* 2000; (2):CD001042
- Cai T et al. *Serenoa repens* associated with *Urtica dioica* (ProstaMEV) and curcumin and quercetin (FlogMEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomized study. *Int J Antimicrob Agents* 2009 Jun; 33(6): 549-53
- Kim YH, Lee YJ. TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation. *J Cell Biochem* 2007 Mar 1; 100(4): 998-1009
- Lee DH et al. Role of Bax in quercetin-induced apoptosis in human prostate cancer cells. *Biochem Pharmacol* 2008 Jun 15; 75(12): 2345-55
- Ma Z et al. Reduction of rat prostate weight by combined quercetin-finasteride treatment is associated with cell cycle deregulation. *J Endocrinol* 2004 Jun; 181(3): 493-507
- Nair HK et al. Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. *Clin Diag Lab Immunol* 2004 Jan; 11(1): 63-69
- Senthilkumar K et al. Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3). *Mol Cell Biochem* 2010 Nov; 344(1-2): 173-84
- Shoskes DA et al. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. *Urology* 1999; 54(6):960-63.
- Shoskes DA et al. Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT. *Urology* 2010 Jun; 75(6): 1249-53
- Vijayababu MR et al. Quercetin downregulates matrix metalloproteinases 2 and 9 proteins expression in prostate cancer cells (PC-3). *Mol Cell Biochem* 2006 Jul; 287(1-2): 109-16
- Bidoli E et al. Dietary vitamins E and C and prostate cancer risk. *Acta Oncol* 2009; 48(6): 890-94
- Christen S, et al. gamma-tocopherol traps mutagenic electrophiles such as NO(X) and complements alpha-tocopherol: physiological implications. *Proc Natl Acad Sci U S A* 1997 Apr 1;94(7):3217-22
- Helzlsouer KJ et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. *J Natl Cancer Inst* 2000; 92:2018-23.
- Ju J et al. Cancer preventive activities of tocopherols and tocotrienols. *Carcinogenesis* 2009 Sep 11.
- Lippman SM et al. Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). *JAMA* 2009 Jan; 301(1):39-51.
- Malafa MP et al. Vitamin E succinate suppresses prostate tumor growth by Gomez Y et al. Zinc levels in prostatic fluid of patients with prostate pathologies. *Invest Clin* 2007 Sep; 48(3): 287-94
- Gonzalez A et al. Zinc intake from supplements and diet and prostate cancer. *Nutr Cancer* 2009; 61(2):206-215.
- Lin SF et al. Profiling of zinc-altered gene expression in human prostate normal vs cancer cells: a time course study. *J Nutr Biochem* 2009 Dec; 20(12): 1000-12
- Yan M et al. Differential response to zinc-induced apoptosis in benign prostate hyperplasia and prostate cancer cells. *J Nutr Biochem* 2010 Aug; 21(8): 687-94
- Inducing apoptosis. *Int J Cancer* 2006; 118(10):2441-47.
- Syed DN et al. Chemoprevention of prostate cancer through dietary agents: progress and promise. *Cancer Epidemiol Biomarkers Prev* 2007; 16(11):2193-2203.
- Barlet A et al. Efficacy of *Pygeum africanum* extract in the treatment of micturitional disorders due to benign prostatic hyperplasia. Evaluation of objective and subjective parameters. A multicenter, randomized, double-blind trial. *Wein Klin Wochenschr* 1990;102:667-73.
- Breza J et al. Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe. *Curr Med Res Opin* 1998; 14(3):127-39.
- Chatelain C et al. Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension. *Urology* 1999 Sep; 54(3):473-78.
- Mantovani F. *Serenoa repens* in benign prostatic hypertrophy: analysis of 2 Italian studies. *Minerva Urol Nefrol* 2010 Dec; 62(4): 335-40

- Papaioannou M et al. NBBS isolated from *Pygeum africanum* bark exhibits androgen antagonistic activity, inhibits AR nuclear translocation and prostate cancer cell growth. *Invest New Drugs* 2010 Dec; 28(6): 729-43
- Papaioannou M et al. The natural compound atraric acid is an antagonist of the human androgen receptor inhibiting cellular invasiveness and prostate cancer cell growth. *J Cell Mol Med* 2009 Aug; 13(8B): 2210-23
- Wilt T et al. *Pygeum africanum* for benign prostatic hyperplasia. *Cochrane Databases of Systematic Reviews* 2002; (1)CD001044
- Yablonsky FP et al. Antiproliferative effect of *Pygeum africanum* extract on rat prostatic fibroblasts. *J Urol* 1997; 157:2381-87.
- Aneschi R et al. *Sereoa repens* (Permixon) reduces intra- and postoperative complications of surgical treatments of benign prostatic hyperplasia. *Minerva Urol Nefrol* 2010 Sep; 62(3): 219-23
- Baron A et al. *Sereoa repens* extract targets mitochondria and activates the intrinsic apoptotic pathway in human prostate cancer cells. *BJU Int* 2009 May; 103(9): 1275-83
- Debruyne Fet al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. *Eur Urol* 2002; 41(5):497-506.
- Mantovani F. *Sereoa repens* in benign prostatic hypertrophy: analysis of 2 Italian studies. *Minerva Urol Nefrol* 2010 Dec; 62(4): 335-40
- Pais P. Potency of a novel saw palmetto ethanol extract, SPET-05, for inhibition of 5alpha-reductase II. *Adv Ther* 2010 Aug; 27(8): 555-63
- Petrangeli E et al. Lipido-sterolic extract of *Sereoa repens* (LSESr, Permixon) treatment affects human prostate cancer cell membrane organization. *J Cell Physiol* 2009 Apr; 219(1): 69-76.
- Sinescu I et al. Long-term efficacy of *sereoa repens* treatment in patients with mild and moderate symptomatic benign prostatic hyperplasia. *Urol Int* 2011; 86(3): 284-49
- Tacklind J et al. *Sereoa repens* for benign prostatic hyperplasia. *Cochrane Database Syst Rev* 2009 Apr 15; (2): CD001423.
- Fibbi B et al. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. *Int J Androl* 2010 Jun 1; 33(3): 475-88
- Galic J, Simunovic D. Prostate disease prevalence with epidemiological and hormonal analysis in randomly selected male population in Croatia. *Coll Anthropol* 2008; 32(4):1195-1202.
- Gilbert R et al. Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. *Cancer Causes Control* 2011 Mar; 22(3): 319-40
- Krishnan AV, Feldman D. Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. *Endocr Relat Cancer* 2010 Jan 29; 17(1): R19-38
- Kristal AR et al. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. *Am J Epidemiol*. 2008 Apr 15; 167(8):925-34.
- Motrich RD et al. Impact of vitamin D receptor activity on experimental autoimmune prostatitis. *J Autoimmun* 2009 Mar; 32(2): 140-48
- Newsom-Davis TE et al. The promiscuous receptor. *BJU Int* 2009 Nov; 104(9): 1204-7.
- Penna G et al. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. *Prostate* 2009 Apr 1; 69(5): 480-93
- Cai T et al. *Sereoa repens* associated with *Urtica dioica* (ProstaMEV) and curcumin and quercetin (FlogMEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomized study. *Int J Antimicrob Agents* 2009 Jun; 33(6): 549-53
- Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. *Phytother Res* 2012 Mar 9; doi:10.1002/ptr.4639
- Dorai T et al. Therapeutic potential of curcumin in human prostate cancer. *Prostate Cancer Prostatic Dis* 2000 Aug; 3(2): 84-93
- Hegde ML et al. Oxidative genome damage and its repair in neurodegenerative diseases: function of transition metals as a double-edged sword. *J Alzheimers Dis* 2011 Jan 1; 24:183-98.
- Herman JG et al. Curcumin blocks CCL2-induced adhesion, motility and invasion, in part, through down-regulation of CCL2 expression and proteolytic activity. *Int J Oncol* 2009 May; 34(5): 1319-27.
- Khor TO et al. Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. *Cancer Res* 2006 Jan. 15; 66(2): 613-21
- Maheshwari RK et al. Multiple biological activities of curcumin: A short review. *Life Sci* 2006 Jan 12
- Marczylo T et al. Comparison of systemic availability of curcumin with that of curcumin formulated with

phosphatidylcholine. *Chemother Pharmacol* 2007, 60, 171-177

Moga MM. Alternative treatment of gallbladder disease. *Med Hypotheses* 2003 Jan; 60(1):143-47

Prucksunand C et al. Phase II clinical trial on effect of the long turmeric (*Curcuma longa* Linn) on healing of peptic ulcer. *Southeast Asian J Trop Med Public Health* 2001 Mar; 32(1):208-15

Shah S et al. Targeting pioneering factor and hormone receptor cooperative pathways to suppress tumor progression. *Cancer Res* 2012 Mar 1; 72(5): 1248-59

Shin SK et al. Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. *Mol Nutr Food Res* 2011 Dec; 55(12): 1829-40

Sikora E et al. Curcumin, inflammation, ageing and age-related diseases. *Immun Ageing* 2010 Jan 17; 7(1): 1

Slusarz A et al. Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer. *Cancer Res* 2010 Apr 15; 70(8) : 3382-90

Surh YJ, Chun KS. Cancer chemopreventive effects of curcumin. *Adv Exp Med Biol* 2007; 595:149-72

University of Maryland: <http://www.umm.edu/altmed/articles/turmeric-000277.htm>

White B, Judkins DZ. Clinical inquiry: does turmeric relieve inflammation conditions? *J Fam Pract* 2011 Mar; 60(3): 155-56

Zhang QY et al. Reducing effect of curcumin on expressions of TNF-alpha, IL-6 and IL-8 in rats with chronic nonbacterial prostatitis. *Zhonghua Nan Ke Xue* 2010 Jan; 16(1): 84-88

***These statements have not been evaluated by the Food and Drug Administration. They should not be considered medical advice. Always consult a doctor for medical advice. This product is not intended to diagnose, treat, cure, or prevent any disease**